Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1

Journal of Virology

Volumn 75, Issue 6, 2001, Pages 2741-2752

  York, J ^a   Follis, K E ^a   Trahey, M ^a   Nyambi, P N ^a   Zolla Pazner, S ^a   Nunberg, J H ^a  

^a UNIVERSITY OF MONTANA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN;

ANTIGEN BINDING; ARTICLE; CELL CULTURE; FLOW CYTOMETRY; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS ADSORPTION; VIRUS NEUTRALIZATION; VIRUS RESISTANCE;

ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; CELL LINE; FLOW CYTOMETRY; GENE PRODUCTS, ENV; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; NEUTRALIZATION TESTS; T-LYMPHOCYTES; TRANSFECTION; VIRION;

EID: 0035120591     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.6.2741-2752.2001     Document Type: Article

References (68)

1. In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity
2. Neulralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: Role of V3-specific antibodies
3. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure
4. Cryptic nature of envelope V3 region epitopes protects primary monocytropic human immunodeficiency virus type 1 from antibody neutralization
5. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals
6. Antibody and virus: Binding and neutralization
7. Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41
8. Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation
9. Jitters jeopardize AIDS vaccine trials
10. Relative resistance of primary HIV-1 isolates to neutralization by soluble CD4
11. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates
12. Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity
13. Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events
14. Analysis of the cleavage site of the human immunodeficiency virus type 1 glycoprotein: Requirement of precursor cleavage for glycoprotein incorporation
15. Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity
16. Continued utilization of CCR5 coreceptor by a newly-adapted T-cell line-adapted isolate of human immunodeficieney virus type 1
17. Physicochemical dissociation of CD4-mediatcd syncytium formation and shedding of human immunodeficiency virus type 1 gp120
18. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G
19. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120
20. Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual
21. Completion of nucleotide sequences of non-syncytium-inducing and syncytium-inducing HIV type 1 variants isolated from the same patient
22. The role of eukaryotic subtilisin-like endoproteases for the activation of human immunodeficiency virus glycoproteins in natural host cells
23. Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry, and make direct CD4-dependent interactions with this chemokine receptor
24. Increased envelope spike density and stability are not required for neutralization resistance of primary human immunodeficiency viruses
25. Production of human monoclonal antibodies specific for conformafional and linear non-V3 epitopes of gp120
26. Quantitative model of antibody- and soluble CD4-mediated neutralization of primary, isolates and T-cell line-adapted strains of human immunodeficiency virus type 1
27. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
28. Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity
29. Fusion-competent vaccines: Broad neutralization of primary isolates of HIV
30. Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus
31. Polarized apical distribution of glycosyl-phosphatidylinositol-anchored proteins in a renal epithelial cell line
32. Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: A mechanism for cellular human immunodeficiency virus 1 infection
33. Evidence that antibody-mediated neutralization of human inmunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage
34. Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the response of their envelope glycoproteins to soluble CD4
35. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120
36. HIV-1 neutralization: The consequences of viral adaptation to growth on transformed T cells
37. Thermodynamic and kinetic analysis of sCD4 binding to HIV-1 virions and of gp120 dissociation
38. Dissociation of gp120 from HIV-1 virions induced by soluble CD4
39. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein
40. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1
41. Turning a corner on HIV neutralization?
42. Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: A new strategy for studying the immunologic relatedness of HIV-1
43. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M
44. Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures
45. Association of host cell surface adhesion receptors and other membrane proteins with HIV and SIV
46. Increase in sensitivity to soluble CD4 by primary HIV type 1 isolates after passage through C8166 cells: Association with sequence differences in the first constant (Cl) region of glycoprotein 120
47. HIV-1 antibody - Debris or virion?
48. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of envelope specificity
49. The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity
50. Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120
51. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding
52. The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection
53. Human antibodies from phage libraries: Neutralizing activity against human immunodeficiency virus type 1 equally improved after expression as Fab and IgG in mammalian cells
54. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer
55. Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding
56. Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop-epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding
57. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates
58. CD4-induced conformational changes in the human immunodeficiency type 1 gp120 glycoprotein: Consequences for virus entry and neutralization
59. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodefidency syndrome: Studies on sequential HIV isolates
60. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding
61. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibody and CD4-based reagents is independent of coreceptor usage
62. Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1
63. Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization
64. Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1
65. Adaptation to persistent growth in the H9 cell line renders a primery isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera
66. The antigenic structure of the HIV gp120 envelope glycoprotein
67. Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization
68. Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry